HBP1 and colitis: These results reveal a new regulatory mechanism that miR‐155/HBP1 axis promotes colitis‐associated intestinal fibrosis via Wnt/β‐catenin signalling pathway and suggest that miR‐155 is a potential therapeutic target for CD treatment.